Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endoplasmic reticulum membrane; Single-pass type I membrane protein. |
Domain |
PF00262 Calreticulin family |
Function |
Functions during spermatogenesis as a chaperone for a range of client proteins that are important for sperm adhesion onto the egg zona pellucida and for subsequent penetration of the zona pellucida. Required for normal sperm migration from the uterus into the oviduct. Required for normal male fertility. Binds calcium ions (By similarity). |
Biological Process |
GO:0006457 protein folding GO:0007338 single fertilization GO:0007339 binding of sperm to zona pellucida GO:0008037 cell recognition GO:0009566 fertilization GO:0009988 cell-cell recognition GO:0035036 sperm-egg recognition |
Molecular Function |
GO:0044183 protein binding involved in protein folding GO:0051082 unfolded protein binding |
Cellular Component |
GO:0005635 nuclear envelope |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CLGN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CLGN in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CLGN in various data sets.
|
Points in the above scatter plot represent the mutation difference of CLGN in various data sets.
|
Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CLGN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CLGN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CLGN. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CLGN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CLGN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CLGN |
Name | calmegin |
Aliases | |
Chromosomal Location | 4q28.3-q31.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CLGN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |